The CREATE-X [28] and KATHERINE [21] trials have transformed clinical practice by showing that capecitabine and T-DM1, respectively, significantly improve outcomes in TNBC and HER2-positive breast cancer patients who did not achieve pCR after neoadjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.